Posted in

Ditching Clopidogrel? New Data Supports NOAC Monotherapy

•Posted inInternal Medicine

Patients with Atrial Fibrillation (AF) who underwent coronary stenting more than one year ago need careful management. The optimal long-term anti-thrombotic plan is debated. The choice involves continuing dual therapy or switching to oral anticoagulant monotherapy. A new study strongly supports NOAC monotherapy as the preferred long-term strategy. Researchers compared a NOAC alone to a NOAC plus clopidogrel for noninferiority on clinical events at one year.

Study Findings: Efficacy of NOAC Monotherapy

The results show NOAC monotherapy was noninferior for the primary composite endpoint. This endpoint included all-cause death, MI, stroke, systemic embolism, and urgent revascularisation. Therefore, patients maintained sufficient protection against ischemic events. Moreover, the rates of major adverse cardiac and cerebrovascular events (MACCE) were similar between the two treatment groups. Consequently, clinicians should feel confident about the thrombotic protection from NOACs alone. Furthermore, international guidelines already suggest oral anticoagulation monotherapy after 12 months post-PCI.

Bleeding Risk: The Key Advantage of NOAC Monotherapy

The principal benefit of transitioning to NOAC monotherapy is the substantial reduction in bleeding risk. Patients receiving the combined therapy (NOAC + clopidogrel) faced a higher incidence of major bleeding events. In contrast, the monotherapy group experienced a significantly lower risk of major bleeding. Specifically, combining a NOAC with clopidogrel—a P2Y12 inhibitor—is associated with a notably elevated risk of haemorrhage. Clinicians must acknowledge this elevated risk. Thus, discontinuing the antiplatelet agent (clopidogrel) substantially improves the safety profile without sacrificing ischemic protection. This risk reduction involves both intracranial and gastrointestinal bleeding. Consequently, this study validates the current shift towards a less intensive antithrombotic strategy in the long term. Finally, this finding is consistent with real-world registry data showing similar MACCE risk but lower major bleeding with NOAC alone.

Frequently Asked Questions

Q1: What is the recommended default antithrombotic strategy after 12 months post-PCI in AF patients?

Anticoagulation monotherapy with a NOAC is the recommended default strategy. This applies after 12 months following percutaneous coronary intervention (PCI) with a drug-eluting stent.

Q2: Why is NOAC monotherapy preferred over combination therapy in this setting?

NOAC monotherapy is preferred because it offers ischemic protection similar to the combination therapy. Importantly, it significantly reduces the patient’s risk of major bleeding complications. This includes gastrointestinal and intracranial haemorrhages.

References

  1. Mukherjee D et al. In AF with drug-eluting stent for ≥1 y, NOACs were noninferior to NOAC + clopidogrel for a composite of adverse clinical events at 1 y. Ann Intern Med. 2026 Feb 03. doi: 10.7326/ANNALS-25-05478-JC. PMID: 41628468.
  2. Jung G, et al. Optimal Antithrombotic Therapy Beyond 1-Year After Coronary Revascularization in Patients With Atrial Fibrillation. J Korean Med Sci. 2024;39(22):e191.
  3. Angiolillo DJ, et al. Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention. Circulation. 2021;143(7):752-766.
  4. Guimarães AC, et al. Meta‐Analysis Comparing Oral Anticoagulant Monotherapy Versus Dual Antithrombotic Therapy in Patients With Atrial Fibrillation and Stable Coronary Artery Disease. J Am Heart Assoc. 2024;13(19):e033320.